查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2103049

全球Duchenne氏肌肉失養症（DMD）流行病學分析與預測：2026年

Global Duchenne Muscular Dystrophy Epidemiology Analysis and Forecast, 2026
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 172 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計在預測期內，Duchenne氏肌肉失養症(DMD) 的全球盛行率將以 2.5% 的複合年成長率成長，從 2026 年的 43 萬例增加到 2035 年的 54 萬例。

Duchenne氏肌肉失養症（DMD）是一種罕見嚴重的X連鎖神經肌肉疾病，由Dystrophin基因突變引起。此病主要影響男性，其特徵為進行性性肌肉萎縮、行走能力喪失、呼吸功能障礙、心臟併發症、預期平均壽命縮短。作為兒童中最常見的肌肉萎縮症症之一，DMD對患者、看護者、醫療保健系統和社會都帶來了沉重的負擔。儘管目前該疾病仍然相對罕見，但診斷能力的提高和公眾意識的增強正在推動診斷率的提高，並加深人們對全球患者群體的了解。

流行病學分析在評估疾病盛行率、發病率、突變分佈、確診患者群體、人口統計特徵、疾病進展模式、存活趨勢和治療合格發揮著至關重要的作用。製藥公司、生物技術公司、醫療保健機構、政策制定者和研究機構越來越依賴流行病學資訊來支持臨床試驗計劃、市場預測、資源分配和罕見疾病策略制定。隨著創新療法的出現，準確的流行病學評估對於了解患者需求和商業性機會比以往任何時候都更重要。

市場促進因素

基因檢測的廣泛應用

市場成長的主要驅動力之一是基因檢測技術的廣泛應用。分子診斷、次世代定序和突變分析技術的進步顯著提高了杜氏肌肉營養不良症（DMD）診斷的準確性和速度。

更早、更可靠地診斷疾病的能力使醫療專業人員能夠更早地識別受影響的個體，從而改善患者管理並建立更豐富的流行病學資料庫。基因檢測服務的普及也有助於更全面地監測疾病和進行人群分析。

人們對罕見遺傳疾病的認知不斷提高

由醫療機構、患者支持團體和研究機構主導的宣傳宣傳活動正在提高醫療保健專業人員和公眾對杜氏肌肉營養不良症 (DMD) 的認知。

公眾意識的提高有助於早期診斷，擴大患者登記的參與範圍，並改善病例報告。這些進展也有助於更準確地估計不同地區的盛行率和發生率。

擴大患者登記和疾病資料庫

國家和國際病患登記系統作為資訊來源，其重要性日益凸顯。這些資料庫收集了有關患者人口統計特徵、基因突變、疾病進展、治療模式和長期預後的寶貴數據。

患者登記的擴展正在加深人們對疾病負擔的了解，並促進更複雜的流行病學預測模型的發展。

擴大治療研發活動

正在研發的DMD治療藥物數量不斷增加，顯著提高了對患者群體資訊的需求。製藥公司需要詳細的流行病學數據來支持臨床試驗招募、監管申報、市場准入計劃和商業性預測。

隨著個人化醫療和基因突變特異性療法的普及，準確分類患者群體的重要性也日益凸顯。

本報告調查了全球Duchenne氏肌肉失養症（DMD）市場，重點關注流行病學趨勢。報告內容包括疾病概述、新發病例和盛行率的趨勢和預測、流行病學建立市場模型、市場規模的趨勢和預測、按治療類型和給藥途徑進行的詳細分析、按地區/主要國家/地區分類的趨勢、主要公司概況以及未來展望。

目錄

第1章執行摘要

  • 報告摘要
  • 主要發現
  • Duchenne氏肌肉失養症（DMD）的流行病學概述
  • 過去和未來的疾病負擔
  • 主要流行病學趨勢和發現
  • 高成長機會與未滿足的需求
  • 主要策略結論

第2章：疾病分析與流行病學

  • Duchenne氏肌肉失養症：概述
  • 疾病分類與突變亞型
    • 適合進行外顯子45跳躍手術的患者群體
    • 外顯子51跳躍患者群體
    • 外顯子53跳躍適應症患者群體
    • 無義變異 DMD
    • 其他基因型
    • 能行走的病人與不能行走的病人
  • 風險因素和疾病負擔
  • 流行病學分析方法
  • 全球流行病學分析
    • 新確診病例數
    • 患者人數
    • 確診患者人數
    • 接受治療的患者人數
    • 按基因突變分類的患者數量
    • 年齡分佈
    • 依嚴重程度分佈
    • 對能行走的患者和不能行走的患者進行分析。
  • 流行病學預測
    • 全球病例預測
    • 全球疾病流行預測
    • 預測確診患者人數
    • 預測合格治療條件的患者人數
    • 基因突變預測

第3章 市場動態

  • 市場概覽
  • 促進因素
  • 抑制因子
  • 機會
  • 任務

第4章 商業化與市場進入

  • 市場進入概覽
  • 價格趨勢
  • 贖回環境
  • 罕見疾病津貼項目
  • 健康技術評估 (HTA) 的考慮因素
  • 患者支持計劃
  • 商業化策略
  • 相關利益者分析

第5章：創新與通路展望

  • 管道概覽
  • 按開發階段分類的管道
    • 發現階段
    • 臨床前階段
    • 第一階段
    • 第二階段
    • 第三階段
  • 按模式分類的管道
    • 基因治療
    • 外顯子跳躍療法
    • 基因編輯療法
    • 細胞療法
    • 小分子藥物
    • 基於RNA的療法
  • 按作用機制分類的管道
    • Dystrophin替代療法
    • 埃克森美孚跳過
    • 組蛋白去乙醯化酶抑制
    • 優營養素調整
    • 基因編輯方法
    • 促進肌肉再生
  • 臨床試驗現狀

第6章 當前治療狀況

  • 治療模式概述
  • 治療指南和護理標準
  • 藥物治療
    • 皮質類固醇
    • 外顯子跳躍療法
    • 基因治療
    • 組蛋白去乙醯化酶抑制劑
    • 支持性藥物治療
  • 非藥物療法
    • 物理治療
    • 呼吸系統護理
    • 心臟管理
    • 整形外科管理
    • 營養管理
  • 已通過核准藥物的現狀
    • 德弗拉紮法院（Emflaza、Pyquvi、Jaythari）
    • Eteplirsene（Exondys 51）
    • Vyondys 53
    • 阿蒙迪斯 45
    • 維爾特普索
    • Delangestrogen moxeparvovec（Elevidys）
    • Vamorolone（Agamree）
    • 吉比諾司他（杜維札特）

第7章 全球Duchenne氏肌肉失養症（DMD）市場：規模與預測

  • 市場定義和範圍
  • 過往市場分析
  • 全球市場預測
  • 基於流行病學的建立市場模型
  • 按治療類型進行的預測
  • 透過行政途徑進行預測
  • 按分銷管道預測
  • 區域預測
  • 情境分析

第8章 全球Duchenne氏肌肉失養症（DMD）市場：依細分市場分類

  • 治療類型
    • 皮質類固醇
    • 外顯子跳躍療法
    • 基因治療
    • 支持性護理
  • 按基因突變類型
    • 埃克森美孚45號跳過適應
    • 埃克森美孚 51 號跳過適應
    • 埃克森美孚 53 跳過適應
    • 其他基因突變
  • 透過行政途徑
    • 口服
    • 靜脈注射
    • 其他
  • 最終用戶
    • 醫院
    • 專科診所
    • 神經肌肉疾病專科中心
    • 居家醫療
  • 透過分銷管道
    • 醫院藥房
    • 專科藥房/零售藥房
    • 網路藥房

第9章 區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
    • 流行病學導論
    • 市場規模及預測
    • 需求促進因素
    • 區域法規概述
    • 競爭優勢

第10章：主要國家分析

  • 加拿大
  • 德國
  • 中國
  • 日本
  • 印度

第11章 法規與政策概述

  • 世界法規概覽
  • 美國 - FDA框架
  • 歐洲EMA框架
  • 日本 - PMDA框架
  • 印度 - CDSCO 框架
  • 中國 - 國家藥品管理局框架
  • 定價和兌換政策
  • 罕見疾病激勵計劃
  • 未來監理趨勢

第12章 競爭格局

  • 市場結構分析
  • 市佔率評估
  • 競爭性標竿分析
  • 產品定位矩陣
  • 管道競爭分析
  • 策略聯盟和授權協議
  • M&A
  • 競爭對手資訊儀錶板

第13章：公司簡介

  • Sarepta Therapeutics
  • NS Pharma
  • Catalyst Pharmaceuticals
  • Italfarmaco SpA
  • PTC Therapeutics
  • Roche Holding AG
  • Pfizer
  • REGENXBIO
  • Solid Biosciences
  • Dyne Therapeutics

第14章 未來展望

  • 未來流行病學趨勢
  • 新療法的創新
  • 基因編輯的前景
  • 精準醫療的發展
  • 2045年之前的市場預測情景
  • 關鍵策略建議
  • 分析師結論

第15章：調查方法

簡介目錄
Product Code: KSI-008842

The Global Duchenne Muscular Dystrophy prevelance is projected to increase at a CAGR of 2.5% for the forecast period, growing from 0.43 million patients in 2026 to 0.54 million patients by 2035.

Duchenne Muscular Dystrophy (DMD) is a rare, severe, X-linked genetic neuromuscular disorder caused by mutations in the dystrophin gene. The disease primarily affects males and is characterized by progressive muscle degeneration, loss of ambulation, respiratory decline, cardiac complications, and reduced life expectancy. As one of the most common forms of muscular dystrophy in children, DMD imposes a substantial burden on patients, caregivers, healthcare systems, and society. Although the disease remains relatively rare, increasing diagnostic capabilities and enhanced disease awareness are improving identification rates and expanding the understanding of global patient populations.

Epidemiology analysis plays a crucial role in evaluating disease prevalence, incidence, mutation distribution, diagnosed patient populations, demographic characteristics, disease progression patterns, survival trends, and treatment eligibility. Pharmaceutical companies, biotechnology firms, healthcare providers, policymakers, and research organizations increasingly depend on epidemiological intelligence to support clinical trial planning, market forecasting, healthcare resource allocation, and rare disease strategy development. As innovative therapies continue to emerge, accurate epidemiological assessments are becoming even more important for understanding patient needs and commercial opportunities.

Market Drivers

Increasing Adoption of Genetic Testing

One of the primary drivers of market growth is the expanding use of genetic testing technologies. Advances in molecular diagnostics, next-generation sequencing, and mutation analysis have significantly improved the accuracy and speed of DMD diagnosis.

Earlier and more reliable diagnosis enables healthcare providers to identify affected individuals sooner, improving patient management and strengthening epidemiological databases. The growing availability of genetic testing services is contributing to more comprehensive disease surveillance and population analysis.

Growing Awareness of Rare Genetic Disorders

Awareness campaigns led by healthcare organizations, patient advocacy groups, and research institutions are improving recognition of DMD among healthcare professionals and the general public.

Enhanced awareness promotes earlier diagnosis, increased participation in patient registries, and improved reporting of disease cases. These developments support more accurate estimates of disease prevalence and incidence across different regions.

Expansion of Patient Registries and Disease Databases

National and international patient registries are becoming increasingly important sources of epidemiological information. These databases collect valuable data regarding patient demographics, genetic mutations, disease progression, treatment patterns, and long-term outcomes.

The expansion of patient registries is improving understanding of disease burden and supporting more sophisticated epidemiological forecasting models.

Growth in Therapeutic Development Activities

The increasing number of DMD therapies under development is creating substantial demand for patient population intelligence. Drug developers require detailed epidemiological data to support clinical trial recruitment, regulatory submissions, market access planning, and commercial forecasting.

As personalized and mutation-specific therapies become more common, the importance of precise patient segmentation continues to grow.

Market Restraints

Underdiagnosis in Developing Regions

Many patients in low- and middle-income countries remain undiagnosed due to limited access to specialized healthcare services, genetic testing facilities, and neuromuscular disease expertise.

Underdiagnosis can result in incomplete epidemiological assessments and may affect the accuracy of global prevalence estimates.

Variability in Diagnostic Practices

Differences in diagnostic criteria, healthcare infrastructure, and disease reporting systems across countries can create inconsistencies in epidemiological data collection.

These variations may complicate comparisons between regions and introduce uncertainty into patient population forecasts.

Limited Long-Term Data Availability

Although patient registries continue to expand, long-term epidemiological data remain limited in some regions. Incomplete datasets may affect the ability to accurately assess disease progression patterns, survival outcomes, and future patient population trends.

Addressing these data gaps remains an important priority for researchers and healthcare organizations.

Technology and Segment Insights

The global Duchenne Muscular Dystrophy epidemiology analysis market can be segmented by patient category, disease stage, mutation type, data source, application, end user, and geography.

By patient category, the market includes prevalent cases, incident cases, diagnosed patients, undiagnosed patients, treated patients, untreated patients, and genetically confirmed patients. Diagnosed and genetically confirmed patients represent significant segments due to the growing use of molecular diagnostic technologies and increasing treatment eligibility assessments.

By disease stage, the market includes early-stage disease, ambulatory patients, non-ambulatory patients, advanced disease, and patients with significant respiratory or cardiac involvement. Early-stage and ambulatory patient populations are receiving increased attention due to the growing availability of therapies designed to intervene before severe disease progression occurs.

By mutation type, the market includes exon deletions, exon duplications, point mutations, nonsense mutations, splice-site mutations, and other genetic abnormalities. Mutation-specific epidemiological analysis is becoming increasingly important as precision medicine approaches target specific genetic subgroups.

By data source, the market includes patient registries, hospital databases, electronic health records, genetic testing laboratories, academic research studies, insurance databases, and government health registries. Patient registries and genetic databases play a central role in disease surveillance and patient population tracking.

By application, the market encompasses prevalence analysis, incidence analysis, disease burden assessment, treatment eligibility evaluation, clinical trial feasibility studies, healthcare planning, and commercial opportunity assessment. Treatment eligibility analysis is becoming increasingly important as advanced therapies target specific patient populations.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms. Pharmaceutical and biotechnology companies account for a major share of demand due to increasing investment in DMD therapeutic development.

Technological advancements are transforming epidemiological analysis through artificial intelligence, predictive analytics, genomics platforms, real-world evidence systems, electronic health records, and integrated patient databases. These technologies improve patient identification, disease modeling, mutation analysis, and long-term forecasting capabilities.

The growing integration of genetic information with epidemiological datasets is enabling more precise patient stratification and supporting the development of targeted treatment approaches. Advanced analytics platforms are also improving the accuracy of prevalence forecasting and healthcare resource planning.

Geographically, North America represents the leading market due to advanced genetic testing infrastructure, strong rare disease research activity, established patient registries, and extensive therapeutic development programs. Europe maintains a significant position supported by collaborative neuromuscular disease networks, comprehensive healthcare systems, and rare disease initiatives. Asia-Pacific is expected to experience substantial growth due to improving healthcare infrastructure, expanding genetic testing access, increasing disease awareness, and growing investments in rare disease research. Latin America and the Middle East & Africa are gradually strengthening diagnostic capabilities and epidemiological surveillance programs.

Competitive and Strategic Outlook

The competitive landscape is characterized by increasing collaboration among pharmaceutical companies, biotechnology firms, patient advocacy organizations, academic institutions, healthcare providers, and epidemiological research organizations.

Stakeholders are investing in patient registries, genetic databases, real-world evidence platforms, and advanced analytics capabilities to improve understanding of disease prevalence and patient demographics. Strategic partnerships are helping organizations expand access to epidemiological data, improve patient identification, and support therapeutic development initiatives.

The increasing focus on personalized medicine and mutation-specific therapies is creating demand for more detailed epidemiological segmentation. Companies are utilizing advanced population analysis to identify treatment-eligible patients, optimize clinical trial recruitment, and support future commercialization strategies.

As therapeutic innovation continues to accelerate, epidemiological intelligence will remain a critical component of strategic decision-making across the DMD healthcare ecosystem.

Conclusion

The global Duchenne Muscular Dystrophy epidemiology analysis market is poised for sustained growth through 2031, supported by increasing adoption of genetic testing, expanding patient registries, growing awareness of rare genetic disorders, and rising investment in therapeutic development. Comprehensive epidemiological analysis remains essential for understanding disease burden, supporting healthcare planning, guiding clinical research, and enabling successful commercialization of emerging therapies. Although challenges related to underdiagnosis, regional data variability, and limited long-term datasets persist, ongoing advancements in genomics, healthcare informatics, and patient data integration are expected to significantly improve the accuracy and value of DMD epidemiological intelligence in the coming years.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Report Overview
  • 1.2 Key Findings
  • 1.3 Duchenne Muscular Dystrophy (DMD) Epidemiology Snapshot
  • 1.4 Historical and Forecast Disease Burden (2025-2045)
  • 1.5 Key Epidemiological Trends and Insights
  • 1.6 High-Growth Opportunities and Unmet Needs
  • 1.7 Key Strategic Conclusions

2. Disease & Epidemiology Analysis

  • 2.1 Introduction to Duchenne Muscular Dystrophy
    • 2.1.1 Disease Definition
    • 2.1.2 Disease Pathophysiology
    • 2.1.3 Genetic Basis and Dystrophin Gene Mutations
    • 2.1.4 Disease Progression and Natural History
    • 2.1.5 Clinical Manifestations
  • 2.2 Disease Classification and Mutation Subtypes
    • 2.2.1 Exon 45 Amenable Population
    • 2.2.2 Exon 51 Amenable Population
    • 2.2.3 Exon 53 Amenable Population
    • 2.2.4 Nonsense Mutation DMD
    • 2.2.5 Other Mutation Types
    • 2.2.6 Ambulatory vs Non-Ambulatory Population
  • 2.3 Risk Factors and Disease Burden
    • 2.3.1 Genetic Risk Factors
    • 2.3.2 Family History and Carrier Status
    • 2.3.3 Mortality and Survival Trends
    • 2.3.4 Quality-of-Life Burden
    • 2.3.5 Economic Burden of Disease
  • 2.4 Epidemiology Methodology
    • 2.4.1 Data Sources and Assumptions
    • 2.4.2 Epidemiology Modeling Framework
    • 2.4.3 Forecasting Methodology (2025-2045)
  • 2.5 Global Epidemiology Analysis
    • 2.5.1 Incident Cases
    • 2.5.2 Prevalent Cases
    • 2.5.3 Diagnosed Prevalent Cases
    • 2.5.4 Treated Patient Population
    • 2.5.5 Mutation-Specific Patient Population
    • 2.5.6 Age-Specific Distribution
    • 2.5.7 Severity-Based Distribution
    • 2.5.8 Ambulatory and Non-Ambulatory Population Analysis
  • 2.6 Epidemiology Forecast (2025-2045)
    • 2.6.1 Global Incidence Forecast
    • 2.6.2 Global Prevalence Forecast
    • 2.6.3 Diagnosed Population Forecast
    • 2.6.4 Treatment-Eligible Population Forecast
    • 2.6.5 Mutation-Specific Forecast

3. Market Dynamics

  • 3.1 Market Overview
  • 3.2 Drivers
    • 3.2.1 Increasing Genetic Testing and Early Diagnosis
    • 3.2.2 Growing Adoption of Mutation-Specific Therapies
    • 3.2.3 Advancements in Gene Therapy
    • 3.2.4 Expansion of Rare Disease Funding Programs
    • 3.2.5 Improved Patient Survival Rates
  • 3.3 Restraints
    • 3.3.1 High Cost of Treatment
    • 3.3.2 Limited Eligible Patient Populations
    • 3.3.3 Regulatory and Clinical Uncertainties
    • 3.3.4 Gene Therapy Safety Concerns
    • 3.3.5 Access and Reimbursement Challenges
  • 3.4 Opportunities
    • 3.4.1 Next-Generation Gene Therapies
    • 3.4.2 Gene Editing Technologies
    • 3.4.3 Combination Therapeutic Approaches
    • 3.4.4 Emerging Market Expansion
    • 3.4.5 Precision Medicine Development
  • 3.5 Challenges
    • 3.5.1 Long-Term Outcome Validation
    • 3.5.2 Manufacturing Complexity
    • 3.5.3 Rare Disease Clinical Trial Recruitment
    • 3.5.4 Market Access Inequalities

4. Commercial & Market Access

  • 4.1 Market Access Overview
  • 4.2 Pricing Landscape
  • 4.3 Reimbursement Environment
  • 4.4 Rare Disease Funding Programs
  • 4.5 Health Technology Assessment Considerations
  • 4.6 Patient Assistance Programs
  • 4.7 Commercialization Strategies
  • 4.8 Stakeholder Analysis
    • 4.8.1 Patients and Advocacy Groups
    • 4.8.2 Physicians and Treatment Centers
    • 4.8.3 Payers and Insurers
    • 4.8.4 Government Agencies

5. Innovation & Pipeline Landscape

  • 5.1 Pipeline Overview
  • 5.2 Pipeline by Development Phase
    • 5.2.1 Discovery Stage
    • 5.2.2 Preclinical Stage
    • 5.2.3 Phase I
    • 5.2.4 Phase II
    • 5.2.5 Phase III
  • 5.3 Pipeline by Modality
    • 5.3.1 Gene Therapy
    • 5.3.2 Exon-Skipping Therapies
    • 5.3.3 Gene Editing Therapies
    • 5.3.4 Cell-Based Therapies
    • 5.3.5 Small Molecules
    • 5.3.6 RNA-Based Therapeutics
  • 5.4 Pipeline by Mechanism of Action
    • 5.4.1 Micro-Dystrophin Replacement
    • 5.4.2 Exon Skipping
    • 5.4.3 Histone Deacetylase Inhibition
    • 5.4.4 Utrophin Modulation
    • 5.4.5 Gene Editing Approaches
    • 5.4.6 Muscle Regeneration Enhancement
  • 5.5 Clinical Trial Landscape
    • 5.5.1 Active Clinical Trials
    • 5.5.2 Recruiting Studies
    • 5.5.3 Completed Studies
    • 5.5.4 Regional Clinical Trial Activity

6. Treatment Landscape

  • 6.1 Treatment Paradigm Overview
  • 6.2 Treatment Guidelines and Standards of Care
  • 6.3 Pharmacological Therapies
    • 6.3.1 Corticosteroids
    • 6.3.2 Exon-Skipping Therapies
    • 6.3.3 Gene Therapies
    • 6.3.4 Histone Deacetylase Inhibitors
    • 6.3.5 Supportive Pharmacotherapy
  • 6.4 Non-Pharmacological Management
    • 6.4.1 Physical Therapy
    • 6.4.2 Respiratory Support
    • 6.4.3 Cardiac Management
    • 6.4.4 Orthopedic Management
    • 6.4.5 Nutritional Support
  • 6.5 Approved Drug Landscape
    • 6.5.1 Deflazacort (Emflaza, Pyquvi, Jaythari)
    • 6.5.2 Eteplirsen (Exondys 51)
    • 6.5.3 Golodirsen (Vyondys 53)
    • 6.5.4 Casimersen (Amondys 45)
    • 6.5.5 Viltolarsen (Viltepso)
    • 6.5.6 Delandistrogene Moxeparvovec (Elevidys)
    • 6.5.7 Vamorolone (Agamree)
    • 6.5.8 Givinostat (Duvyzat)

7. Global Duchenne Muscular Dystrophy Epidemiology Report Size & Forecast

  • 7.1 Market Definition and Scope
  • 7.2 Historical Market Analysis
  • 7.3 Global Market Forecast (2025-2045)
  • 7.4 Epidemiology-Based Market Modeling
  • 7.5 Forecast by Therapy Type
  • 7.6 Forecast by Route of Administration
  • 7.7 Forecast by Distribution Channel
  • 7.8 Forecast by Geography
  • 7.9 Scenario Analysis
    • 7.9.1 Base Case
    • 7.9.2 Optimistic Case
    • 7.9.3 Conservative Case

8. Global Duchenne Muscular Dystrophy Epidemiology Report Segmentation

  • 8.1 By Therapy Type
    • 8.1.1 Corticosteroids
    • 8.1.2 Exon-Skipping Therapies
    • 8.1.3 Gene Therapies
    • 8.1.4 Supportive Therapies
  • 8.2 By Mutation Type
    • 8.2.1 Exon 45 Amenable
    • 8.2.2 Exon 51 Amenable
    • 8.2.3 Exon 53 Amenable
    • 8.2.4 Other Mutations
  • 8.3 By Route of Administration
    • 8.3.1 Oral
    • 8.3.2 Intravenous
    • 8.3.3 Others
  • 8.4 By End User
    • 8.4.1 Hospitals
    • 8.4.2 Specialty Clinics
    • 8.4.3 Neuromuscular Centers
    • 8.4.4 Homecare Settings
  • 8.5 By Distribution Channel
    • 8.5.1 Hospital Pharmacies
    • 8.5.2 Specialty & Retail Pharmacies
    • 8.5.4 Online Pharmacies

9. Geographical Analysis (Regional Level)

  • 9.1 North America
    • 9.1.1 Epidemiology Overview
    • 9.1.2 Market Size and Forecast
    • 9.1.3 Key Growth Drivers
    • 9.1.4 Regional Regulatory Overview
    • 9.1.5 Competitive Intensity
  • 9.2 Europe
    • 9.2.1 Epidemiology Overview
    • 9.2.2 Market Size and Forecast
    • 9.2.3 Key Growth Drivers
    • 9.2.4 Regional Regulatory Overview
    • 9.2.5 Competitive Intensity
  • 9.3 Asia-Pacific
    • 9.3.1 Epidemiology Overview
    • 9.3.2 Market Size and Forecast
    • 9.3.3 Key Growth Drivers
    • 9.3.4 Regional Regulatory Overview
    • 9.3.5 Competitive Intensity
  • 9.4 Latin America
    • 9.4.1 Epidemiology Overview
    • 9.4.2 Market Size and Forecast
    • 9.4.3 Key Growth Drivers
    • 9.4.4 Regional Regulatory Overview
    • 9.4.5 Competitive Intensity
  • 9.5 Middle East & Africa
    • 9.5.1 Epidemiology Overview
    • 9.5.2 Market Size and Forecast
    • 9.5.3 Key Growth Drivers
    • 9.5.4 Regional Regulatory Overview
    • 9.5.5 Competitive Intensity

10. Key Countries Analysis

  • 10.1 United States
  • 10.2 Canada
  • 10.3 Germany
  • 10.4 United Kingdom
  • 10.5 France
  • 10.6 Italy
  • 10.7 Spain
  • 10.8 China
  • 10.9 Japan
  • 10.10 India
  • 10.11 South Korea
  • 10.12 Australia
  • 10.13 Brazil
  • 10.14 Mexico
  • 10.15 Saudi Arabia
  • 10.16 South Africa

11. Regulatory & Policy Landscape

  • 11.1 Global Regulatory Overview
  • 11.2 United States - FDA Framework
    • 11.2.1 Orphan Drug Designation
    • 11.2.2 Accelerated Approval Pathways
    • 11.2.3 Gene Therapy Regulations
  • 11.3 Europe - EMA Framework
    • 11.3.1 Orphan Medicinal Products
    • 11.3.2 Advanced Therapy Medicinal Products (ATMPs)
  • 11.4 Japan - PMDA Framework
    • 11.4.1 Regenerative Medicine Pathways
    • 11.4.2 Conditional Approval Systems
  • 11.5 India - CDSCO Framework
    • 11.5.1 Rare Disease Policies
    • 11.5.2 Gene Therapy Regulatory Environment
  • 11.6 China - NMPA Framework
    • 11.6.1 Rare Disease Regulations
    • 11.6.2 Innovative Therapy Approval Pathways
  • 11.7 Pricing and Reimbursement Policies
  • 11.8 Rare Disease Incentive Programs
  • 11.9 Future Regulatory Trends

12. Competitive Landscape

  • 12.1 Market Structure Analysis
  • 12.2 Market Share Assessment
  • 12.3 Competitive Benchmarking
  • 12.4 Product Positioning Matrix
  • 12.5 Pipeline Competitiveness Analysis
  • 12.6 Strategic Collaborations and Licensing Agreements
  • 12.7 Mergers and Acquisitions
  • 12.8 Competitive Intelligence Dashboard

13. Company Profiles

  • 13.1 Sarepta Therapeutics
    • 13.1.1 Company Overview
    • 13.1.2 Approved Products
      • 13.1.2.1 Exondys 51 (eteplirsen)
      • 13.1.2.2 Vyondys 53 (golodirsen)
      • 13.1.2.3 Amondys 45 (casimersen)
      • 13.1.2.4 Elevidys (delandistrogene moxeparvovec)
    • 13.1.3 Key Indications
    • 13.1.4 Verified DMD Pipeline Assets
    • 13.1.5 Strategic Outlook
  • 13.2 NS Pharma
    • 13.2.1 Company Overview
    • 13.2.2 Approved Product: Viltepso (viltolarsen)
    • 13.2.3 Key Indications
    • 13.2.4 Pipeline Programs
    • 13.2.5 Strategic Outlook
  • 13.3 Catalyst Pharmaceuticals
    • 13.3.1 Company Overview
    • 13.3.2 Approved Products: Agamere (vamorolone)
    • 13.3.3 Key Indications
    • 13.3.4 Pipeline Programs
    • 13.3.5 Strategic Outlook
  • 13.4 Italfarmaco SpA
    • 13.4.1 Company Overview
    • 13.4.2 Approved Product: Duvyzat (givinostat)
    • 13.4.3 Key Indications
    • 13.4.4 Pipeline Programs
    • 13.4.5 Strategic Outlook
  • 13.5 PTC Therapeutics
    • 13.5.1 Company Overview
    • 13.5.2 Approved Product: Translarna (ataluren)*
    • 13.5.3 Key Indications
    • 13.5.4 Pipeline Programs
    • 13.5.5 Strategic Outlook
  • 13.6 Roche Holding AG
    • 13.6.1 Company Overview
    • 13.6.2 DMD Partnerships and Commercial Rights
    • 13.6.3 Key Indications
    • 13.6.4 Pipeline and Development Programs
    • 13.6.5 Strategic Outlook
  • 13.7 Pfizer
    • 13.7.1 Company Overview
    • 13.7.2 Historical DMD Development Programs
    • 13.7.3 Key Indications
    • 13.7.4 Pipeline Activities
    • 13.7.5 Strategic Outlook
  • 13.8 REGENXBIO
    • 13.8.1 Company Overview
    • 13.8.2 DMD Gene Therapy Programs
    • 13.8.3 Key Indications
    • 13.8.4 Pipeline Status
    • 13.8.5 Strategic Outlook
  • 13.9 Solid Biosciences
    • 13.9.1 Company Overview
    • 13.9.2 DMD Development Programs
    • 13.9.3 Key Indications
    • 13.9.4 Pipeline Status
    • 13.9.5 Strategic Outlook
  • 13.10 Dyne Therapeutics
    • 13.10.1 Company Overview
    • 13.10.2 DMD Development Programs
    • 13.10.3 Key Indications
    • 13.10.4 Pipeline Status
    • 13.10.5 Strategic Outlook

14. Future Outlook

  • 14.1 Future Epidemiology Trends
  • 14.2 Emerging Therapeutic Innovations
  • 14.3 Gene Editing Outlook
  • 14.4 Precision Medicine Evolution
  • 14.5 Market Forecast Scenarios Through 2045
  • 14.6 Key Strategic Recommendations
  • 14.7 Analyst Conclusions

15. Methodology

  • 15.1 Research Methodology Overview
  • 15.2 Secondary Research Sources
  • 15.3 Primary Research Framework
  • 15.4 Epidemiology Modeling Methodology
  • 15.5 Forecasting Assumptions
  • 15.6 Data Validation Process
  • 15.7 Quality Control Framework
  • 15.8 Disclaimer and Limitations